

Click for full [Prescribing Information](#) for
Bupivacaine Spinal (bupivacaine hydrochloride in dextrose injection, USP)

Click for full [Prescribing Information](#) for
Marcaine® Spinal (bupivacaine hydrochloride in dextrose injection, USP)

Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045



April 2, 2026

**Notification of Emergency Date Extension for
Bupivacaine Spinal (bupivacaine hydrochloride in dextrose injection, USP) and
Marcaine® Spinal (bupivacaine hydrochloride in dextrose injection, USP)**

Dear Valued Customer,

Pfizer has received approval from the U.S. Food and Drug Administration (FDA) of our emergency request to extend the use date for several lots of **Bupivacaine Spinal (bupivacaine hydrochloride in dextrose injection, USP)** and **Marcaine® Spinal (bupivacaine hydrochloride in dextrose injection, USP)** to mitigate shortages of these critical products. Impacted lot numbers and extended use dates are outlined in the tables at the end of this letter.

If a replacement product becomes available during the extension period, customers are expected to replace and properly dispose of this affected lot as soon as possible. The FDA's [website](#), which lists extended use dates to assist with drug shortages, has also been updated to reflect this information.

If you have any questions, please call our Customer Service Department at 1-844-646-4398.

Thank you,

Jennifer Meek
Portfolio Director, Anesthesia
Global Hospital & Biosimilars, U.S. Commercial

Emergency Extended Use Dating: Bupivacaine Spinal (bupivacaine hydrochloride in dextrose injection, USP)

Unit of Sale NDC	Unit of Use NDC	Product Description	Lots	Labeled Expiration Date	Extended Use Date
00409-3613-01	00409-3613-11	Bupivacaine Spinal (bupivacaine HCl 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% Injection, USP)	LD2831 LD2832 LD2855 LE2563	02/28/26	02/28/27

Emergency Extended Use Dating: Marcaine® Spinal (bupivacaine hydrochloride in dextrose injection, USP)

Unit of Sale NDC	Unit of Use NDC	Product Description	Lots	Labeled Expiration Date	Extended Use Date
00409-1761-10	00409-1761-18	Marcaine® Spinal (bupivacaine HCl 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% Injection, USP)	GH4433	10/01/25	10/01/26
00409-1761-62	N/A	Marcaine® Spinal (bupivacaine HCl 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% Injection, USP)	GY7951	02/01/2026	02/01/27